GLP-1
Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.
Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
Galapagos NV announced that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors, and a consultant of the company and its subsidiaries.
PhaseBio Pharmaceuticals, based in Malvern, Penn. and San Diego, announced that its antiplatelet drug PB2452 had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).
Galapagos NV published its annual report for the financial year 2018.
PRESS RELEASES